HINGHAM, Mass., Sept. 19, 2022 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), continuing its recent success of strengthening its Scientific Advisory Board with the recent recruitment of Key Opinion Leaders (KOLs), today announced that Ripal T. Gandhi, MD, FSVM, will join the Company’s robust Scientific Advisory Board (SAB). Dr. Gandhi is an interventional oncologist and a member of the Miami Cardiac & Vascular Institute and Miami Cancer Institute physician team where he specializes in minimally invasive treatments for peripheral vascular disease, cancer, and other diseases, and has a history of being an innovator in the Interventional Robotics field.
“Today we announce a very exciting addition to our Scientific Advisory Board, as Dr. Gandhi is a robotic pioneer, has considerable experience with previous generations of endovascular surgical robotics, and clearly knows the challenges they present and how our LIBERTY Robotic System can address most, if not all of them,” commented Harel Gadot, CEO, President, and Chairman.”
“Having completed over 100 robotic cases in the interventional space using larger bulky capital equipment, I was immediately drawn to the LIBERTY technology and the barriers it breaks down,” Commented Dr. Gandhi. “I am excited to bring my first-hand experience to help guide the Microbot team’s revolutionary approach to create the first ever fully disposable robotic system, which I believe will be central in driving robotic adoption in this space.”
- Dr. Ripal Gandhi is experienced in treating cancers, peripheral arterial disease (PAD), thoracic aortic aneurysms, abdominal aortic aneurysms (AAA), uterine fibroids, deep venous thrombosis, pulmonary embolism, varicoceles, and varicose veins. Dr. Gandhi is a clinical professor at the University of South Florida School of Medicine and FIU Herbert Wertheim College of Medicine, training physicians in vascular/endovascular, interventional radiology and interventional oncology techniques. While at Memorial Sloan-Kettering, he investigated hepatic embolization and other minimally invasive therapies for liver cancer and other malignancies. Dr. Gandhi received his medical degree from Northwestern University Medical School, completed surgical internships at Cornell University Medical Center and NY Presbyterian Hospital, followed by residency training and fellowship at UCLA Medical Center. Dr. Gandhi is the recipient of multiple awards, co-authored the textbook Interventional Oncology, and is a fellow of the Society of Vascular Medicine, Society of Interventional Radiology and a program director for the International Symposium on Endovascular Therapy (ISET) and Symposium on Clinical Interventional Oncology (CIO).
About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies, focused primarily on both natural and artificial lumens within the human body. Microbot’s current proprietary technological platforms provide the foundation for the development of a Multi Generation Pipeline Portfolio (MGPP).
Microbot Medical was founded in 2010 by Harel Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of improving clinical outcomes for patients and increasing accessibility through the use of micro-robotic technologies. Further information about Microbot Medical is available at http://www.microbotmedical.com.
